The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

Global g-protein coupled receptors (GPCRs) market growth is Driven by Rising drug discovery activities, expanding applications in targeted therapeutics, and increasing prevalence of chronic and ...

One of the most notable breakout stories in the obesity drug market of 2025 was the clinical-stage biotech Structure ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as ...

A GPS-like technique has been used to track G protein-coupled receptor movement, revealing how these essential receptors function. Although G protein-coupled receptors (GPCRs) are crucial to the ...

Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...

Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...

A recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role of astrocytic G protein-coupled receptors (GPCRs). This research offers ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure ...